Gut microbiome structure and metabolic activity in inflammatory bowel disease

被引:0
|
作者
Eric A. Franzosa
Alexandra Sirota-Madi
Julian Avila-Pacheco
Nadine Fornelos
Henry J. Haiser
Stefan Reinker
Tommi Vatanen
A. Brantley Hall
Himel Mallick
Lauren J. McIver
Jenny S. Sauk
Robin G. Wilson
Betsy W. Stevens
Justin M. Scott
Kerry Pierce
Amy A. Deik
Kevin Bullock
Floris Imhann
Jeffrey A. Porter
Alexandra Zhernakova
Jingyuan Fu
Rinse K. Weersma
Cisca Wijmenga
Clary B. Clish
Hera Vlamakis
Curtis Huttenhower
Ramnik J. Xavier
机构
[1] Broad Institute of MIT and Harvard,Department of Biostatistics
[2] Harvard School of Public Health,Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease
[3] Novartis Institute for Biomedical Research Inc.,Department of Immunology, K.G. Jebsen Coeliac Disease Research Centre
[4] Massachusetts General Hospital and Harvard Medical School,Center for Microbiome Informatics and Therapeutics
[5] Department of Gastroenterology and Hepatology,undefined
[6] University of Groningen and University Medical Center Groningen,undefined
[7] Department of Genetics,undefined
[8] University of Groningen and University Medical Center Groningen,undefined
[9] Novartis Institute for Biomedical Research Inc.,undefined
[10] Department of Pediatrics,undefined
[11] University of Groningen and University Medical Center Groningen,undefined
[12] University of Oslo,undefined
[13] Massachusetts Institute of Technology,undefined
来源
Nature Microbiology | 2019年 / 4卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The inflammatory bowel diseases (IBDs), which include Crohn’s disease (CD) and ulcerative colitis (UC), are multifactorial chronic conditions of the gastrointestinal tract. While IBD has been associated with dramatic changes in the gut microbiota, changes in the gut metabolome—the molecular interface between host and microbiota—are less well understood. To address this gap, we performed untargeted metabolomic and shotgun metagenomic profiling of cross-sectional stool samples from discovery (n = 155) and validation (n = 65) cohorts of CD, UC and non-IBD control patients. Metabolomic and metagenomic profiles were broadly correlated with faecal calprotectin levels (a measure of gut inflammation). Across >8,000 measured metabolite features, we identified chemicals and chemical classes that were differentially abundant in IBD, including enrichments for sphingolipids and bile acids, and depletions for triacylglycerols and tetrapyrroles. While > 50% of differentially abundant metabolite features were uncharacterized, many could be assigned putative roles through metabolomic ‘guilt by association’ (covariation with known metabolites). Differentially abundant species and functions from the metagenomic profiles reflected adaptation to oxidative stress in the IBD gut, and were individually consistent with previous findings. Integrating these data, however, we identified 122 robust associations between differentially abundant species and well-characterized differentially abundant metabolites, indicating possible mechanistic relationships that are perturbed in IBD. Finally, we found that metabolome- and metagenome-based classifiers of IBD status were highly accurate and, like the vast majority of individual trends, generalized well to the independent validation cohort. Our findings thus provide an improved understanding of perturbations of the microbiome–metabolome interface in IBD, including identification of many potential diagnostic and therapeutic targets.
引用
收藏
页码:293 / 305
页数:12
相关论文
共 50 条
  • [31] Gut microbiome as a potential biomarker of cancer risk in inflammatory bowel disease
    Jones, Ryan Lane
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2022, 26 (01): : 40 - 43
  • [32] Inflammatory bowel disease biomarkers revealed by the human gut microbiome network
    Mirko Hu
    Guido Caldarelli
    Tommaso Gili
    Scientific Reports, 13
  • [33] The Neglected Gut Microbiome: Fungi, Protozoa, and Bacteriophages in Inflammatory Bowel Disease
    Guzzo, Gina L.
    Andrews, Jane M.
    Weyrich, Laura S.
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (07) : 1112 - 1122
  • [34] Propionate Fermentative Genes of the Gut Microbiome Decrease in Inflammatory Bowel Disease
    Medina, Juan Manuel
    Fernandez-Lopez, Raul
    Crespo, Javier
    Cruz, Fernando de la
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (10)
  • [35] Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease
    Sultan, Salma
    El-Mowafy, Mohammed
    Elgaml, Abdelaziz
    Ahmed, Tamer A. E.
    Hassan, Hebatoallah
    Mottawea, Walid
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [36] The microbiome and inflammatory bowel disease
    Glassner, Kerri L.
    Abraham, Bincy P.
    Quigley, Eamonn M. M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (01) : 16 - 27
  • [37] The Microbiome in Inflammatory Bowel Disease
    Jauregui-Amezaga, Aranzazu
    Smet, Annemieke
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
  • [38] The Microbiome and Inflammatory Bowel Disease
    Steinberg, Sabine Hazan
    Frochtzwajg, Daniel
    Murray, Jessica
    PRACTICAL GASTROENTEROLOGY, 2018, 42 (01) : 28 - 31
  • [39] GUT MICROBIOME ASSOCIATED CIRCULATING INFLAMMATORY PROTEINS IN PATIENTS WITH EITHER INFLAMMATORY BOWEL DISEASE OR IRRITABLE BOWEL SYNDROME
    Ren, Yi Ping
    Sim, Shi Min
    Liu, Lin
    Kwa, Wit Thun
    Tan, Bernice
    Mok, John
    Pang, Shu Kuan
    Hartono, Juanda Leo
    Siah, Kewin Tien Ho
    Lee, Jonathan W.
    GASTROENTEROLOGY, 2024, 166 (05) : S1460 - S1461
  • [40] Gut Microbiome Changes Are Different Between Ankylosing Spondylitis and Inflammatory Bowel Disease, and Correlate with Disease Activity in Both Diseases
    Sternes, Peter
    Brett, Laurel
    Phipps, Julie
    Ciccia, Francesco
    de Guzman, Erika
    Morrison, Mark
    Holtmann, Gerald
    Klingberg, Eva
    McIvor, Carolyn
    Forsblad-d'Elia, Helena
    Brown, Matthew
    ARTHRITIS & RHEUMATOLOGY, 2020, 72